TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00543387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5108
Description: MK-5108 will be administered orally, every 12 hours (Q12H) during the first 2 days of each cycle. Cycle length will be 14-21 days in Panel 1 and 21 days in Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5108
Description: MK-5108 will be administered orally, every 12 hours (Q12H) during the first 2 days of each cycle. Cycle length will be 14-21 days in Panel 1 and 21 days in Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5108
Description: MK-5108 will be administered orally, every 12 hours (Q12H) during the first 2 days of each cycle. Cycle length will be 14-21 days in Panel 1 and 21 days in Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5108
Description: MK-5108 will be administered orally, every 12 hours (Q12H) during the first 2 days of each cycle. Cycle length will be 14-21 days in Panel 1 and 21 days in Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5108
Description: MK-5108 will be administered orally, every 12 hours (Q12H) during the first 2 days of each cycle. Cycle length will be 14-21 days in Panel 1 and 21 days in Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5108
Description: MK-5108 will be administered orally, every 12 hours (Q12H) during the first 2 days of each cycle. Cycle length will be 14-21 days in Panel 1 and 21 days in Panel 2.
Study: NCT02403115

Intervention type: OTHER
Intervention: Serum collection
Description: Clinical tests (renal function, complete blood count, CRP, ANA, dsDNA, urinalysis) will be performed at fixed time intervals (6, 12, 24 and 36 months) and the surplus of blood sample will form the serum bank used for the study
Study: NCT00543387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5108
Description: MK-5108 will be administered orally, every 12 hours (Q12H) during the first 2 days of each cycle. Cycle length will be 14-21 days in Panel 1 and 21 days in Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5108
Description: MK-5108 will be administered orally, every 12 hours (Q12H) during the first 2 days of each cycle. Cycle length will be 14-21 days in Panel 1 and 21 days in Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel will be administered intravenously (I.V.) at a dose of 60 mg/m\^2 Q12H during the first 2 days of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel will be administered intravenously (I.V.) at a dose of 60 mg/m\^2 Q12H during the first 2 days of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel will be administered intravenously (I.V.) at a dose of 60 mg/m\^2 Q12H during the first 2 days of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel will be administered intravenously (I.V.) at a dose of 60 mg/m\^2 Q12H during the first 2 days of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel will be administered intravenously (I.V.) at a dose of 60 mg/m\^2 Q12H during the first 2 days of each 21-day cycle.
Study: NCT01063153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osmotic Release Methylphenidate
Description: During a 6 week treatment period, adult subjects with ADHD are prescribed, in an open label fashion, once daily doses of osmotic release methylphenidate to a maximum daily dose of 144 mg. Efficacy and tolerability assessments are completed, in addition to EEG and cognitive testing. Healthy adults without ADHD will not receive medication.
Study: NCT02717052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (S)-ketamine (Main study)
Description: Ketanest® S (Esketaminhydrochlorid) 5mg/ml and 25mg/ml ampoules; Actavis Italy S.P.A./Pfizer Corporation Austria GmbH~Dosis: 0.25mg/kg bodyweight i.v. over 40 Minutes (ending 10 minutes before PET measurement)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (S)-ketamine (Pilot II)
Description: Ketanest® S (Esketaminhydrochlorid) 5mg/ml and 25mg/ml ampoules; Actavis Italy S.P.A./Pfizer Corporation Austria GmbH~Dosis: 0.10mg/kg bodyweight i.v. bolus applied over 5 minutes (starting 15 minutes before PET measurement) and continuous infusion of 0.30mg/kg bodyweight i.v. applied over the course of 130 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (R,S)-ketamine (Pilot II)
Description: Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma~Dosis: 0.20mg/kg bodyweight i.v. bolus applied over 5 minutes (starting 15 minutes before PET measurement) and continuous infusion of 0.60mg/kg bodyweight applied i.v. over the course of 130 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline solution i.v. over 40 Minutes (ending 10 minutes before PET measurement)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PILOT Study II: PET1
Description: \[11C\]DASB PET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PILOT Study II: PET1
Description: \[11C\]DASB PET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PILOT Study II: PET2
Description: \[11C\]DASB PET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PILOT Study II: PET2
Description: \[11C\]DASB PET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Main Study: PET1
Description: \[11C\]DASB PET
Study: NCT03261583

Intervention type: OTHER
Intervention: Thoracis Surgery - Common care
Description: Observational study. It is only a matter of collecting clinical data.
Study: NCT02076412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib Disodium
Description: Fostamatinib Disodium tablet 100 mg or 150 mg PO bid (morning and evening) over the course of 24 weeks.
Study: NCT02717052

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Main Study: PET1
Description: \[11C\]DASB PET
Study: NCT02076412

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo tablet PO bid (morning and evening)
Study: NCT03670615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will exercise at TRI according to an individualized exercise prescription.

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise Education
Description: Exercise education/ treatment as usual will include routine advice about physical activity for older adults.

Intervention type: OTHER
Group type: OTHER
Intervention: Sham tDCS
Description: The same procedure for tDCS will be used for the sham condition, except without active current.
Study: NCT01108614

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Intensive HIV psychological counseling ,Increased methadone dosage under individualized treatment principle, enhance randomized urine test, strengthen family and social support , partner notification and routine HIV testing, condom promotion, STD referral services.
Study: NCT02717052

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Main Study: PET2
Description: \[11C\]DASB PET

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Main Study: PET2
Description: \[11C\]DASB PET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PILOT Study I: PET1
Description: \[11C\]DASB PET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PILOT Study I: PET2
Description: \[11C\]DASB PET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (R,S)-ketamine (Pilot I)
Description: Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma~Dosis: 0.50mg/kg bodyweight i.v. over 40 Minutes (ending 10 minutes before PET measurement)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (R,S)-ketamine (Pilot III)
Description: Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma~Dosis: 0.80mg/kg bodyweight i.v. over 50

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PILOT Study III: PET1
Description: \[11C\]DASB PET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PILOT Study III: PET2
Description: \[11C\]DASB PET
Study: NCT02431208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered orally (PO) until loss of clinical benefit, withdrawal, or study end. Cohort B1 will receive 10, 15, or 25 mg, ascending-dose lenalidomide, on Days 1-14 of each 21-day cycle. Cohort C will receive 10 mg on Days 1-14 of each 21-day cycle, beginning in Cycle 4. Cohort E (combination with daratumumab) will receive 10, 15, or 25 mg on Days 1-21 of each 28-day cycle. Participants in Cohort E1 will receive ascending-dose lenalidomide, and those in Cohort E2 will receive lenalidomide at the MTD as determined in Cohort E1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered orally (PO) until loss of clinical benefit, withdrawal, or study end. Cohort B1 will receive 10, 15, or 25 mg, ascending-dose lenalidomide, on Days 1-14 of each 21-day cycle. Cohort C will receive 10 mg on Days 1-14 of each 21-day cycle, beginning in Cycle 4. Cohort E (combination with daratumumab) will receive 10, 15, or 25 mg on Days 1-21 of each 28-day cycle. Participants in Cohort E1 will receive ascending-dose lenalidomide, and those in Cohort E2 will receive lenalidomide at the MTD as determined in Cohort E1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered orally (PO) until loss of clinical benefit, withdrawal, or study end. Cohort B1 will receive 10, 15, or 25 mg, ascending-dose lenalidomide, on Days 1-14 of each 21-day cycle. Cohort C will receive 10 mg on Days 1-14 of each 21-day cycle, beginning in Cycle 4. Cohort E (combination with daratumumab) will receive 10, 15, or 25 mg on Days 1-21 of each 28-day cycle. Participants in Cohort E1 will receive ascending-dose lenalidomide, and those in Cohort E2 will receive lenalidomide at the MTD as determined in Cohort E1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered orally (PO) until loss of clinical benefit, withdrawal, or study end. Cohort B1 will receive 10, 15, or 25 mg, ascending-dose lenalidomide, on Days 1-14 of each 21-day cycle. Cohort C will receive 10 mg on Days 1-14 of each 21-day cycle, beginning in Cycle 4. Cohort E (combination with daratumumab) will receive 10, 15, or 25 mg on Days 1-21 of each 28-day cycle. Participants in Cohort E1 will receive ascending-dose lenalidomide, and those in Cohort E2 will receive lenalidomide at the MTD as determined in Cohort E1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be administered PO until loss of clinical benefit, withdrawal, or study end. Cohort F (combination with daratumumab) will receive 2 or 4 mg on Days 1-21 of each 28-day cycle. Participants in Cohort F1 will receive ascending-dose pomalidomide, and those in Cohort F2 will receive pomalidomide at the MTD as determined in Cohort F1.
Study: NCT03369977

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioGlue Surgical Adhesive
Description: BioGlue (produced by CryoLife in Kennesaw, GA) is a surgical adhesive with two components respectively purified bovine serum albumin (BSA) and Glutaraldehyde (their proportions are 4:1). Crosslinked bonds (covalent bonds) of Glutaraldehyde cross-link the protein on the surface of the tissue and the amino residue of the bovine serum albumin. BioGlue also adheres to the synthetic matrix material by a mechanical interlocking mechanism in the space of graft matrix.

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional Surgical Repair
Description: Traditional surgical repair as determined by the surgeon
Study: NCT01559051

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lipoaspiration with Local anesthesia
Description: Patients undergo a liposuction under local Anethesia. The AD-SVF are then isolated and infused IV and by inhalation delivery.
Study: NCT02200276

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Influenza
Study: NCT02761382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-based psychological treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-specific psychological treatment
Study: NCT04178720

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lehfilcon A contact lenses
Description: Investigational silicone hydrogel contact lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comfilcon A contact lenses
Description: Commercially available silicone hydrogel contact lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CLEAR CARE
Description: Hydrogen peroxide-based system for cleaning and disinfecting silicone hydrogel contact lenses
Study: NCT02998697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous Sulfate
Description: Ferrous sulfate 200 mg t.i.d for 90 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Lactose 200 mg t.i.d for 90 days
Study: NCT03749889

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 100 g carbs
Description: Participants will be assigned a diet of 100g carbs max for the day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MyPlate
Description: 40-65% of daily intake is from carbohydrates
Study: NCT02749617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apixaban
Description: 2.5 mg PO BID
Study: NCT05491902

Intervention type: DIAGNOSTIC_TEST
Intervention: [C11] Leucine PET scan
Description: Each participant will receive an i.v. bolus of the PET radioligand, \[11C\]-Leucine (\<100 μg), for each scan. \[11C\]-Leucine is a PET radioligand has been used and studied clinically (17-23) at micro-doses (\<100 μg) with no adverse effects.

Intervention type: DIAGNOSTIC_TEST
Intervention: [C11] Leucine PET scan
Description: Each participant will receive an i.v. bolus of the PET radioligand, \[11C\]-Leucine (\<100 μg), for each scan. \[11C\]-Leucine is a PET radioligand has been used and studied clinically (17-23) at micro-doses (\<100 μg) with no adverse effects.

Intervention type: DIAGNOSTIC_TEST
Intervention: [C11] Leucine PET scan
Description: Each participant will receive an i.v. bolus of the PET radioligand, \[11C\]-Leucine (\<100 μg), for each scan. \[11C\]-Leucine is a PET radioligand has been used and studied clinically (17-23) at micro-doses (\<100 μg) with no adverse effects.

Intervention type: DIAGNOSTIC_TEST
Intervention: [18F] Flutemetamol PET scan
Description: Each participant will receive an i.v. bolus of the PET radioligand, \[18F\]-Flutemetamol (\< 10 μg), for each scan.

Intervention type: DIAGNOSTIC_TEST
Intervention: [18F] Flutemetamol PET scan
Description: Each participant will receive an i.v. bolus of the PET radioligand, \[18F\]-Flutemetamol (\< 10 μg), for each scan.

Intervention type: DIAGNOSTIC_TEST
Intervention: [18F] Flutemetamol PET scan
Description: Each participant will receive an i.v. bolus of the PET radioligand, \[18F\]-Flutemetamol (\< 10 μg), for each scan.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scan
Description: Scans will be performed on a 1.5T Philips scanner including a 3D T1-weighted scan for co-registration with PET scans and rating of hippocampal atrophy, as well as standard T1 and T2-weighted sequences for rating of white matter lesions.
Study: NCT04178720

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLEAR CARE
Description: Hydrogen peroxide-based system for cleaning and disinfecting silicone hydrogel contact lenses
Study: NCT04499625

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sinus floor elevation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sinus floor elevation using an ultrasonic device
Study: NCT02137096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide phosphate
Description: Etoposide is one of three drugs used in the high-dose conditioning phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is one of the drugs used in the high-dose conditioning phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Ifosfamide is one of the drugs used in the high-dose conditioning phase

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplantation
Description: Autologous Stem Cell Transplantation follows the high-dose chemotherapy phase of the arm.
Study: NCT02705196

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: delolimogene mupadenorepvec
Description: oncolytic virus encoding TMZ-CD40L and 4-1BBL

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: delolimogene mupadenorepvec
Description: oncolytic virus encoding TMZ-CD40L and 4-1BBL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: chemotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: anti-PD-L1 antibody
Study: NCT00513435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saracatinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00930930

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given orally

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Venous blood draw
Description: Venous blood (2-3 tablespoons) will be taken for germline DNA analysis to complement the correlative studies in the tumor tissue. Blood can be drawn at any time prior, during, or after completion of study treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Venous blood draw
Description: Venous blood (2-3 tablespoons) will be taken for germline DNA analysis to complement the correlative studies in the tumor tissue. Blood can be drawn at any time prior, during, or after completion of study treatment
Study: NCT04308629

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Study: NCT03053843

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mediterranean diet plus extra virgin olive oil
Description: The patients in the intervention group will receive 1 liter of EVOO per week free of charge and dietary advice on how to follow a Mediterranean diet with contacts every two months. Dietary intervention will be carried out by nutritionists with previous experience in the PREDIMED study. All of them were registered, trained and certified for developing the PREDIMED intervention protocol that is similar to the one to be carried out in this study. The theoretical sessions with patients about dietary education shall be conducted in telephone form, using the internet and sending comprehensive written material to their homes that includes recipes, shopping lists, menus and explanations of typical food in the Mediterranean diet
Study: NCT05641636

Intervention type: DIAGNOSTIC_TEST
Intervention: 12-lead ECG, hormone and lipid blood tests, echocardiography (Echo-CG), cardiopulmonary exercise testing (CPET) and pulse wave analysis
Description: Echocardiography - standart protocol. Pulse wave characteristics were obtained using finger photopletysmography (PPG) (Angioscan-01, AngioScan-Electronics) from an infrared light sensor. Endothelial function was also evaluated using occlusion index and shear rate during post-occlusive reactive hyperemia (PORH). CPET was conducted on a treadmill (Intertrack 8100, Schiller, Switzerland) with a breath-by-breath algorithm of gas exchange analysis (Cardiovit CS-200 Ergo-Spiro, Schiller, Switzerland), using Bruce, modified Bruce or Naughton protocols depending on the level of physical tolerance.

Intervention type: DIAGNOSTIC_TEST
Intervention: 12-lead ECG, hormone and lipid blood tests, echocardiography (Echo-CG), cardiopulmonary exercise testing (CPET) and pulse wave analysis
Description: Echocardiography - standart protocol. Pulse wave characteristics were obtained using finger photopletysmography (PPG) (Angioscan-01, AngioScan-Electronics) from an infrared light sensor. Endothelial function was also evaluated using occlusion index and shear rate during post-occlusive reactive hyperemia (PORH). CPET was conducted on a treadmill (Intertrack 8100, Schiller, Switzerland) with a breath-by-breath algorithm of gas exchange analysis (Cardiovit CS-200 Ergo-Spiro, Schiller, Switzerland), using Bruce, modified Bruce or Naughton protocols depending on the level of physical tolerance.
Study: NCT00623870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5045337
Description: Multiple ascending doses
Study: NCT01814124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy plus exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Advice and home exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advice and home exercise
Study: NCT02431208

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: Pomalidomide will be administered PO until loss of clinical benefit, withdrawal, or study end. Cohort F (combination with daratumumab) will receive 2 or 4 mg on Days 1-21 of each 28-day cycle. Participants in Cohort F1 will receive ascending-dose pomalidomide, and those in Cohort F2 will receive pomalidomide at the MTD as determined in Cohort F1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: Pomalidomide will be administered PO until loss of clinical benefit, withdrawal, or study end. Cohort F (combination with daratumumab) will receive 2 or 4 mg on Days 1-21 of each 28-day cycle. Participants in Cohort F1 will receive ascending-dose pomalidomide, and those in Cohort F2 will receive pomalidomide at the MTD as determined in Cohort F1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Participants will receive either 20mg or 40mg of dexamethasone PO every 7 days from Day 1 of each cycle.
Study: NCT01541930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK567
Description: Once or twice daily, for 14 days, up to 30 g per day
Study: NCT02484703

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo PO BID. Study medication will first be administered on Day 1, and only the morning dose will be given on the last day of treatment (Week 26).